This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wong, I. H. N. Articles by Johnson, P. J. Search for Related Content PubMed PubMed Citation Articles by Wong, I. H. N. Articles by Johnson, P. J.

Quantitative Analysis of Circulating Tumor Cells in Peripheral Blood of Osteosarcoma Patients Using Osteoblast-specific Messenger RNA Markers: A Pilot Study¹

Departments of Anatomical and Cellular Pathology [I. H. N. W.] and Clinical Oncology [P. J. J.], The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong SAR, China, and Massachusetts General Hospital, Boston, Massachusetts 02114 [A. T. C.]

Metastasis is a major cause of mortality and morbidity in osteosarcoma (OS) patients. To monitor tumor dissemination, we assessed the circulating tumor burden in OS patients by semiquantitative reverse transcription-PCR using osteocalcin, osteonectin, osteopontin, and type I collagen (COLL) mRNAs as molecular markers. We distinguished levels of the mRNAs in peripheral blood between OS patients and healthy subjects using an OS-derived cell line (Saos-2) as a reference standard. We prospectively analyzed 40 peripheral blood samples from 11 OS patients at diagnosis and 29 healthy subjects. In all 29 (100%) healthy subjects, we detected osteocalcin, osteonectin, and osteopontin mRNAs that were most likely attributed to illegitimate transcription in normal hematopoietic cells. In contrast, we found low COLL mRNA levels in only 35% (10 of 29) of healthy subjects, but significantly higher COLL mRNA levels in 91% (10 of 11) of OS patients (P < 0.0001). The reverse transcription-PCR assay for COLL mRNA was sensitive down to the detection of 10 Saos-2 cells among 10⁶ normal peripheral blood nucleated cells. The upper limit of COLL mRNA determined among the healthy subjects was found exceeded by six OS patients. The substantially elevated COLL mRNA levels in peripheral blood seemed to originate from circulating malignant cells in these six OS patients, all of whom subsequently developed clinical metastases within 12 months of diagnosis (P = 0.002). Conversely, no metastases were detected in the remaining OS patients with normal COLL mRNA levels. Quantification of COLL mRNA may prove valuable for diagnosing OS micrometastasis and assessing prognosis.

This article has been cited by other articles:

				I. H.N. Wong The Sporadic Nature of Shedding Cells in Blood: Multiple RNA Diagnostic Testing and Prognostication of Cancer Progression Clin. Chem., September 1, 2003; 49(9): 1429 - 1431. [Full Text] [PDF]

				L. Rainen, U. Oelmueller, S. Jurgensen, R. Wyrich, C. Ballas, J. Schram, C. Herdman, D. Bankaitis-Davis, N. Nicholls, D. Trollinger, et al. Stabilization of mRNA Expression in Whole Blood Samples Clin. Chem., November 1, 2002; 48(11): 1883 - 1890. [Abstract] [Full Text] [PDF]